Transplantation - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Transplantation - Pipeline Review, H2 2013 market report to its offering
Transplantation - Pipeline Review, H2 2013


, 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Transplantation - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Transplantation.
- A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Transplantation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Transplantation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Hospira, Inc.
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Osiris Therapeutics, Inc.
Athersys, Inc.
GlaxoSmithKline plc
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
AbGenomics International, Inc.
Emergent BioSolutions Inc.
Oxford BioMedica plc
Pharming Group N.V.
Vectura Group plc
BioLineRx, Ltd.
Novartis AG
Isotechnika Pharma Inc.
Samyang Corporation
Astellas Pharma Inc.
ViroPharma Incorporated
Cell Therapeutics, Inc.
Genmab A/S
Exelixis, Inc.
Celldex Therapeutics, Inc.
Antisense Therapeutics Limited
LifeCycle Pharma A/S
Mesoblast Ltd
Biovitrum AB
NPS Pharmaceuticals, Inc.
Circadian Technologies Limited
Cleveland BioLabs, Inc.
Accentia Biopharmaceuticals, Inc.
La Jolla Pharmaceutical Company
Jazz Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc.
Soligenix, Inc.
NeoStem, Inc.
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Synta Pharmaceuticals Corp.
MediPost Co., Ltd.
Hansa Medical AB
Proteo, Inc.
Cellerant Therapeutics, Inc.
Digna Biotech, S.L.
Spectrum Pharmaceuticals, Inc.
Viron Therapeutics, Inc.
Palau Pharma S.A
Actinium Pharmaceuticals, Inc.
Pharmagenesis, Inc.
Pharmalink AB
Wellstat Therapeutics Corporation
Argos Therapeutics, Inc.
APT Pharmaceuticals, Inc.
Alder Biopharmaceuticals Inc.
Gene Signal International SA.
ApoImmune, Inc.
Recoly N.V.
Opsona Therapeutics Ltd.
TetraLogic Pharmaceuticals
Conatus Pharmaceuticals Inc.
MSM Protein Technologies, Inc.
Angion Biomedica Corp.
NovImmune SA
TcL Pharma SAS
Polyphor Ltd.
Omeros Corporation
iBio, Inc.
Kiadis Pharma B.V.
CG Therapeutics, Inc.
Bellicum Pharmaceuticals, Inc.
Sirnaomics, Inc.
USV Limited.
Limerick BioPharma, Inc.
KYORIN Pharmaceutical Co., Ltd.
Tolera Therapeutics, Inc.
TaiGen Biotechnology Co., Ltd.
Medistem, Inc.
KAHR medical Ltd.
Medestea Research & Production S.p.A.
NasVax Ltd.
Ikaria Inc.
REGiMMUNE Corporation
ADIENNE Pharma & Biotech
TikoMed AB
Nephrx Corporation
Dr. Falk Pharma GmbH
Dompe Farmaceutici S.p.A.
AIMM Therapeutics B.V.
Amplimmune, Inc.
Lycera Corp.
Bio Sidus S.A.
Icon Bioscience, Inc.
Therapure Biopharma Inc.
FCB-Pharmicell Co.,Ltd.
iTherX Pharmaceuticals Inc.
ToleroTech Inc.
CellAct Pharma GmbH
Sigmoid Pharma.
America Stem Cell, Inc.

To view the table of contents for this market research report please visit